Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment, By End-use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2024 - 2030

Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment, By End-use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2024 - 2030

Cervical Cancer Treatment Market Growth & Trends

The global cervical cancer treatment market size is expected to reach USD 11.74 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased treatment penetration and rising disease incidence are projected to drive the market growth over the next few years. Although, sexually transmitted HPV is a major cause, the disease can also be triggered by other factors, such as oral contraceptives, multiple sexual partners, smoking, and HIV infection. There are more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous cell carcinoma is the most common type and it accounts for nearly 85% of the overall cases.

The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines - Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.

Cervical Cancer Treatment Market Report Highlights

• Squamous cell carcinoma type dominated the market and accounted for the largest revenue share of 71.1% in 2023. This growth is attributed to persistent infection with high-risk human papillomavirus (HPV) subtypes, mainly HPV 16 and 18, which account for most cases.
• Chemotherapy treatment led the market and accounted for the largest revenue share of 33.9% in 2023. This growth is attributed to the advancements in drug development that have significantly enhanced treatment options for cervical adenocarcinoma.
• Hospitals & clinics segment dominated the market and accounted for the largest revenue share of 65.0% in 2023. This growth is attributed to the enhanced delivery procedures in hospitals & clinics with offerings such as targeted therapy, radiation therapy, immunotherapy, minimally invasive surgeries, and many other methods.
• The North America cervical cancer treatment market dominated the global market and accounted for the largest revenue share of 39.4% in 2023.

Please note The report will be delivered in 2-3 business days upon order notification.